Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

OncoTargets and Therapy is a prestigious, peer-reviewed journal dedicated to the rapid dissemination of research in the fields of oncology and pharmacology. Published by DOVE MEDICAL PRESS LTD in New Zealand since 2008, this journal has embraced the open access model, ensuring that critical cancer-related research is freely accessible to a global audience. With an impressive impact factor reflected by its Q2 ranking in both the Oncology and Pharmacology (medical) categories for 2023, as well as Scopus rankings placing it in the top 91st percentile in pharmacology and the 84th percentile in oncology, OncoTargets and Therapy stands out as a vital resource for researchers, clinicians, and students alike. The journal focuses on therapeutics, novel drug discoveries, and clinical trials, encouraging collaborative efforts to combat cancer effectively. By providing a platform for groundbreaking studies and comprehensive reviews, it plays a crucial role in advancing knowledge and practice in these critical areas of medical science.

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.